Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β-elemene scaffold

References

• Zhai B, Zhang N, Han X, et al. Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. Biomed Pharmacother. 2019;114:108812.
   PubMed Web of Science ®Google Scholar
• Xie T. Elemene antitumor drugs: molecular compatibility theory and its applications in new drug development and clinical practice. 1st ed. Amsterdam: Elsevier; 2022.
   Google Scholar
• Zheng F, Tang Q, Zheng X, et al. Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer. Exp Mol Med. 2018;50:121.
   PubMed Web of Science ®Google Scholar
• Long J, Liu Z, Hui L. Anti-tumor effect and mechanistic study of elemene on pancreatic carcinoma. BMC Complem Altern M. 2019;19:133.
   PubMed Web of Science ®Google Scholar
• Xu L, Guo T, Qu X, et al. β-Elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts. Cell Biol Int. 2018;42:1377.
   PubMed Web of Science ®Google Scholar
• Xie L, Zhang J, Yan H, et al. β-Elemene induced apoptosis and senescence of triple-negative breast cancer cells through IGF1/IGF1R pathway. Tissue Cell. 2022;79:101914.
   PubMed Web of Science ®Google Scholar
• Cai B, Ma L, Nong S, et al. β-Elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation. Oncol Lett. 2018;16:6019.
   PubMed Web of Science ®Google Scholar
• Li C-L, Chang L, Guo L, et al. β-Elemene induces caspasedependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Asian Pac J Cancer Prev. 2014;15:10407.
   PubMedGoogle Scholar
• Wang G, Li X, Huang F, et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 2005;62:881.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Qu J, et al. β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang T, Xu S, et al. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway. Eur J Med Chem. 2017;135:414.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu G, Zhang Y, et al. Synthesis and in vitro anti-proliferative activity of β-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase. Bioorg Med Chem. 2009;17:1118.
   PubMedGoogle Scholar
• Wang B, Peng X, Sun R, et al. Systematic review of β-Elemene injection as adjunctive treatment for lung cancer. Chin J Integr Med. 2012;18:813.
   PubMed Web of Science ®Google Scholar
• Hu Q, Bai L, Zhu Z, et al. β-Elemene-loaded polymeric micelles intensify anti-carcinoma efficacy and alleviate side effects. Chinese Chem Lett. 2020;31:915.
   Web of Science ®Google Scholar
• Jiang L, Li A, Tan Y, et al. Clinical observation of elemene injection combined with cisplatin in the treatment of malignant pleural and peritoneal effusion. Med Sci J Central South China. 2020;48:428.
   Google Scholar
• Wang Z, Li Y, Zhou F, et al. β-Elemene enhances anticancer bone neoplasms efficacy of paclitaxel through regulation of GPR124 in bone neoplasms cells. Oncol Lett. 2018;16(2):2143.
   PubMed Web of Science ®Google Scholar
• Cheng H, Ge X, Zhuo S, et al. β-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2. Front Pharmacol. 2018;9:1413.
   PubMed Web of Science ®Google Scholar
• Gao Y, Mao N-D, Che H, et al. Novel hydroxyl carboximates derived from β-elemene: design, synthesis and anti-tumour activities evaluation. J Enzym Inhib Med Chem. 2022;37:2403.
   PubMedGoogle Scholar
• Ye Y, Qi X, Xu B, et al. Nickel-catalyzed cross-electrophile allylation of vinyl bromides and the modification of anti-tumour natural medicine β-elemene. Chem Sci. 2022;13:6959.
   PubMed Web of Science ®Google Scholar
• Bai R, Zhu J, Bai Z, et al. Second generation β-elemene nitric oxide derivatives with reasonable linkers: potential hybrids against malignant brain glioma. J Enzym Inhib Med Chem. 2022;37:379.
   PubMed Web of Science ®Google Scholar
• Qi X, Jiang S, Hui Z, et al. Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles. Bioorgan Med Chem. 2022;74:117049.
   PubMed Web of Science ®Google Scholar
• Kumar V, Kundu S, Singh A, et al. Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective. Curr Neuropharmacol. 2022;20:158.
   PubMed Web of Science ®Google Scholar
• He X, Li Z, Zhuo X-T, et al. Novel selective histone deacetylase 6 (HDAC6) inhibitors: a patent review (2016-2019). Recent Pat anti-Cancer Drug Dis. 2020;15:32.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang H, Lirussi F, et al. Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol. 2020;182:114224.
   PubMed Web of Science ®Google Scholar
• Newbold A, Falkenberg KJ, Prince HM, Johnstone RW. How do tumor cells respond to HDAC inhibition? FEBS J. 2016;283(22):4032–4046.
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194.
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38.
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6:579.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769.
   PubMed Web of Science ®Google Scholar
• Eckschlager T, Plch J, Stiborova M, et al. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:1414.
   PubMed Web of Science ®Google Scholar
• Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4:505.
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12:3997.
   PubMed Web of Science ®Google Scholar
• Suraweera A, O’byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.
   PubMed Web of Science ®Google Scholar
• Diyabalanage HV, Granda ML, Hooker JM. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 2013;329(1):1–8.
   PubMed Web of Science ®Google Scholar
• Thurn KT, Thomas S, Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011;7:263.
   PubMed Web of Science ®Google Scholar
• Luan Y, Li J, Bernatchez JA, et al. Kinase and histone deacetylase hybrid inhibitors for cancer therapy. J Med Chem. 2019;62:3171.
   PubMed Web of Science ®Google Scholar
• Li Y, Luo X, Guo Q, et al. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl) -7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4/9 (CDK4/9) and histone deacetlyase1 (HDAC1) against malignant cancer. J Med Chem. 2018;61:3166.
   PubMed Web of Science ®Google Scholar
• Huang Y, Dong G, Li H, et al. Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections. J Med Chem. 2018;61:6056.
   PubMed Web of Science ®Google Scholar
• Zhang K, Lai F, Lin S, et al. Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases. J Med Chem. 2019;62:6992.
   PubMed Web of Science ®Google Scholar
• Rangasamy L, Ortín I, Zapico JM, et al. New dual CK2/HDAC1 inhibitors with nanomolar inhibitory activity against both enzymes. ACS Med Chem Lett. 2020;11:713.
   PubMed Web of Science ®Google Scholar
• Liu J, Qian C, Zhu Y, et al. Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold. Bioorgan Med Chem. 2018;26:747.
   PubMed Web of Science ®Google Scholar
• Zang J, Liang X, Huang Y, et al. Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously. J Med Chem. 2018;61:5304.
   PubMed Web of Science ®Google Scholar
• He X, Zhuo X-T, Gao Y, et al. β-Elemene derivatives produced from SeO2-mediated oxidation reaction. Royal Soc Open Sci. 2020;7:200038.
   PubMed Web of Science ®Google Scholar
• Watson PJ, Millard CJ, Riley AM, et al. Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat Commun. 2016;7:11262.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Keusch JJ, Wang L, et al. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol. 2016;12:748.
   PubMed Web of Science ®Google Scholar